138 related articles for article (PubMed ID: 26371421)
1. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Pinciroli P; Won H; Iyer G; Canevari S; Colecchia M; Giannatempo P; Raggi D; Pierotti MA; De Braud FG; Solit DB; Rosenberg JE; Berger MF; Necchi A
Clin Genitourin Cancer; 2016 Feb; 14(1):e81-90. PubMed ID: 26371421
[No Abstract] [Full Text] [Related]
2. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
Palma N; Morris JC; Ali SM; Ross JS; Pal SK
Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722
[No Abstract] [Full Text] [Related]
3. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Bellmunt J; Lalani AA; Jacobus S; Wankowicz SA; Polacek L; Takeda DY; Harshman LC; Wagle N; Moreno I; Lundgren K; Bossé D; Van Allen EM; Choueiri TK; Rosenberg JE
Br J Cancer; 2018 Sep; 119(6):707-712. PubMed ID: 30220708
[TBL] [Abstract][Full Text] [Related]
5. Response of refractory Ewing sarcoma to pazopanib.
Alcindor T
Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
[No Abstract] [Full Text] [Related]
6. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
9. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE
Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
13. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib for the treatment of breast cancer.
Amiri-Kordestani L; Tan AR; Swain SM
Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
16. [Anti-ErbB targeted therapy and urothelial tumors].
Amsellem-Ouazana D; Goldwasser F; Bieche I; Lidereau R; Zerbib M
Prog Urol; 2005 Dec; 15(6 Suppl 1):1229-35. PubMed ID: 16734210
[No Abstract] [Full Text] [Related]
17. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
18. Targeting Signaling Transduction Pathways in Bladder Cancer.
Abbosh PH; McConkey DJ; Plimack ER
Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
[TBL] [Abstract][Full Text] [Related]
19. p53 and treatment of bladder cancer.
Cote RJ; Esrig D; Groshen S; Jones PA; Skinner DG
Nature; 1997 Jan; 385(6612):123-5. PubMed ID: 8990112
[No Abstract] [Full Text] [Related]
20. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
[No Abstract] [Full Text] [Related]
[Next] [New Search]